Teriparatide increases hip & spine BMD, particularly in type I osteogenesis imperfecta .
This report has been verified
by one or more authors of the
original publication.
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Evaluation of teriparatide treatment in adults with osteogenesis imperfecta
J Clin Invest. 2014 Feb 3;124(2):491-8. doi: 10.1172/JCI71101.79 patients with osteogenesis imperfecta (OI) were randomized to receive either teriparatide (recombinant human parathyroid hormone) or a placebo administered subcutaneously daily for 18 months. The purpose of this proof-of-concept study was to determine whether teriparatide increased bone formation and positively affected skeletal mass and strength versus a placebo. The results at 18 months indicated that teriparatide significantly increased areal bone mineral density at the lumbar spine and total hip, as well as other bone formation markers. Post-hoc testing revealed significant differences between groups in type 1 OI patients, but not in type III/IV OI patients. Fracture risk was found to be similar, but the study was not adequately powered to detect a difference in fracture risk.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
